Ann: Final Phase IIb AIPAC clinical trial results for Efti in MBC, page-42

Hang in there Hodgie. As pointed out by AFR, price plunge could just be associated with new holders unaware that the trial had moved on to the sub groups and read it as a fail. I still can’t figure out why on earth the first bullet point was the negative news. I kind of beggars belief. If you are trying to sell something you don’t open with your most negative attribute, surely. I’m still scratching my head about it.

But we are still in the uptrend channel. Lag3 is coming into focus and we could have our first approved Lag3 treatment in March. Its going to heat up regardless of what Immutep does.

Let the market digest these great results. Immutep’s got plenty on the go and lots of cash. The good news will keep coming.